



ASIAN CENTRE FOR LIVER DISEASES & TRANSPLANTATION

6A Napier Rd #02-37 Gleneagles Hospital Annexe Block
Singapore 258500 Tel: +65 64762088 Fax: +65 64763088

ASX-listed, Singapore-based liver centre ACLDT net profit rises 60.2% to S\$0.8 million in 1H2012; proposes interim dividend of A\$0.001 per share

- Revenue grew to S\$11.0 million in 1H2012 from S\$9.8 million in 1H2011 from 11.6% increase in total number of patient transactions
- Net profit increased S\$0.3 million on the back of a 12.5% revenue growth and improved operating margins
- Net asset value per share rose by 0.21 S cent to 1.67 S cents as at 29 February 2012 from 1.46 S cent as at 31 August 2011

<u>Singapore Dollars</u>	1H2012 (S\$'000)	1H2011 (S\$'000)	Change (%)
Revenue	10,997	9,774	12.5
Expenses	(10,040)	(9,199)	9.1
Net Profit to members (after tax)	828	517	60.2
Earnings Per Share (S cents)	0.44	0.27	

Singapore, 13 April 2012 – The Asian Centre for Liver Disease and Transplantation (“ACLDT”, ASX:AJJ), the region’s leading liver treatment and transplantation centre, announced today that it recorded a net profit attributable to shareholders for the six months ended 29 February 2012 (“1H2012”) of S\$0.8 million on the back of S\$11.0 million revenue. The Board proposed an interim dividend of A\$0.001 for 1H2012.

Half-year revenue of the medical centre based in Gleneagles Hospital in Singapore rose to S\$11.0 million due mainly to a 11.6% increase in patient transactions to 7,848 from 7,034. The Group has also seen a higher number of patients coming from Mongolia, Myanmar and UAE for consultations and treatment, while core markets from Indonesia, Malaysia and Singapore remained strong.

The Group’s expenses increased by 9.1% to S\$10.0 million from S\$9.2 million due mainly to higher purchased cost from revenue growth, increased employee benefits and operating lease expenses from the new liver clinic at Mount Elizabeth Medical Centre opened in September 2011, and higher professional fees of S\$0.2 million related to the proposed collaboration with University of Pittsburgh Medical Centre (“UPMC”) to establish a Comprehensive Transplant Centre (“CTC”) in Singapore, as announced in December 2011.

The Company’s balance sheet remains healthy. Cash and cash equivalents stood at S\$3.3 million as at 29 February 2012 (after paying FY2011 final dividends of S\$0.5 million) compared to S\$3.7 million a year earlier. De-consolidation of the Vietnam

For personal use only

operations resulted in a S\$0.5 million decrease of property, plant and equipment, and reduction of S\$0.3 million of other payables, bringing net asset to S\$3.1 million as at 29 February 2012.

Earnings per share for 1H2012 was 0.44 S cent compared to 0.27 S cent a year earlier. Net Asset Value per share as at 29 February 2012 stood at 1.67 S cents, compared to 1.46 S cents as at 31 August 2011.

To reward shareholders for their support, the Board proposes an interim dividend of A\$0.001 per share. Once approved, it would represent 30.7% of 1H2012 net profit after tax attributable to members and approximately 2.2% annualised dividend yield based on A\$0.09 share price as at 12 April 2012.

Commenting on the results, Dato' Dr Kai Chah Tan, ACLDT's lead surgeon and Executive Chairman, said: "The increase in patient transactions underscores our efforts to strengthen our competencies with the addition of more surgeons and the opening of an additional liver clinic in Mount Elizabeth Medical Centre."

- End of Release -

About Asian Centre for Liver Diseases and Transplantation

Asian Centre for Liver Diseases and Transplantation ("ACLDT") was established in 1994 in Singapore. Today, it is one of Asia's foremost Liver Centres with out-patient facilities as well as a dedicated in-patient Liver Ward and Intensive Care Unit to complement its highly successful Living Donor Liver Transplantation (LDLT) Programme.

ACLDT is led by renowned hepatobiliary expert and liver transplant surgeon, Dato' Dr Kai Chah Tan (Dr K C Tan), who started the Liver Transplant Programme at the King's College Hospital London, the UK. Together with a multi-disciplinary team of experienced specialist physicians and surgeons, Dr Tan developed it into one of the largest in Europe and performed many pioneering operations including the first 'split-liver' transplant from a single donor to two recipients.

ACLDT is the first private medical centre in South-east Asia to have performed 193 living donor liver transplants as at 31 March 2012. Dr K C Tan has personally performed more than 600 liver transplants. On average, ACLDT treats 8,000 patients a year, of which over 90% are international patients from South-east Asia, South Asia, Indochina, the Middle East and Russia.

With a team of highly-trained specialists, state-of-the-art facilities and equipment, ACLDT is a one-stop specialist medical hub that provides seamless and comprehensive treatment for adults and children with liver and gastro diseases. Given the vast experience of ACLDT and its highly successful LDLT Programme, it has also become an important referral centre for treatment of acute liver failure and liver transplants.

ACLDT was listed on the Australian Securities Exchange in September 2009 (ASX:AJJ).

It opened its first overseas liver centre in Ho Chi Minh City, Vietnam, in September 2010.

For further information, please visit www.asianlivercentre.com.sg

Investor Relations contact:

WeR1 Consultants Pte Ltd

38A Circular Road, Singapore 049394

Tel: +65 6737 4844, Fax: +65 6737 4944

Josephine Auxilio, josephine@wer1.net

For personal use only